16 April 2003 16:09 [Source: ICIS news]
HOUSTON (CNI)--Biopharmaceuticals developer Genzyme General said Wednesday 2003 first quarter net income more than doubled to $61.9m (Euro57.3m) on a 30% rise in revenues to $314m.
For the period ended 31 March, Cambridge, Massachusetts-based Genzyme posted earnings/share (eps) of 28 cents compared to 2002 first quarter eps of 14 cents.
Sales of renal drug Renagel nearly doubled to $58.8m while sales of enzyme replacement therapy Cerezyme rose13% to $167m.
Henri Termeer, chairman and chief executive of Genzyme, said the company had a very strong quarter.
He added: "Our Renagel franchise is on track with end-user demand driving solid growth in product sales. We are also generating excellent growth and momentum within our therapeutics franchise, which we expect will continue with product launches in a number of major markets during the second half of this year."
Second quarter eps are expected to be in the 28-30 cents range, the company said.
Genzyme General confirmed its 2003 eps guidance of $1.25-1.35 excluding $39m or 11 cents/share in amortization.
Genzyme General develops and markets therapeutic products and diagnostic products and services. It is a division of biotechnology company Genzyme Corporation.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|